Previous 10 | Next 10 |
August 20, 2019 Palm Beach, FL –August 20, 2019 – Cancer drug market revenues have been steadily rising in the past few years and all indicators predict that they will continue to rise over the next several years. According to industry sources, in 20118 oncology ...
DPW Holdings (NYSEMKT: DPW ) +287% as its subsidiary, Digital Power Lending, LLC relaunched monthlyinterest.com More news on: DPW Holdings, Inc., Yuma Energy, Inc., China Green Agriculture, Inc., Stocks on the move, Read more ...
Moleculin Biotech (NASDAQ: MBRX ): Q2 GAAP EPS of -$0.03 beats by $0.09 . More news on: Moleculin Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOUSTON , Aug. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the se...
August 13, 2019 Palm Beach, FL –August 13, 2019 – For decades, big (and small) pharma companies have been trying to find ways to cure or at least devise better treatments for all types of cancers. While the war has not been won to find a cure, there have been many, m...
HOUSTON , Aug. 13, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its proof of concept clinical trial to ...
August 6, 2019 Palm Beach, FL –August 6, 2019 – According to an industry report , the global oncology/cancer drugs market (which was valued at $97,401 Million in 2017) is estimated to reach at $176,509 Million by 2025, registering a CAGR of 7.6% from 2018 to 2025....
HOUSTON , Aug. 6, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that a paper entitled "Immunological Reprogra...
Outlook Therapeutics (NASDAQ: OTLK ) +15%. More news on: Outlook Therapeutics, Inc., Safe-T Group Ltd, Acasti Pharma Inc., Stocks on the move, Read more ...
July 18, 2019 Palm Beach, FL –July 18, 2019 – Acute myeloid leukemia (AML) is a cancer that is rarely seen before age 45 with the average age of onset around 65. It is the most common of the four major types of leukemia. Without treatment, AML is often deadly wi...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...